Full metadata record
DC FieldValueLanguage
dc.creatorMurillo, O. (Oihana)-
dc.creatorArina, A. (Ainhoa)-
dc.creatorHervas-Stubbs, S. (Sandra)-
dc.creatorGupta, A. (Anjana)-
dc.creatorMcCluskey, B. (Brandon)-
dc.creatorDubrot, J. (Juan)-
dc.creatorPalazon, A. (Asís)-
dc.creatorAzpilicueta, A. (Arantza)-
dc.creatorOchoa, M.C. (María Carmen)-
dc.creatorAlfaro, C. (Carlos)-
dc.creatorSolano, S. (Sarai)-
dc.creatorPerez-Gracia, J.L. (Jose Luis)-
dc.creatorOyahobi, B.O. (Babatunde O.)-
dc.creatorMelero, I. (Ignacio)-
dc.date.accessioned2012-04-24T15:50:25Z-
dc.date.available2012-04-24T15:50:25Z-
dc.date.issued2008-
dc.identifier.citationMurillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008 Nov 1;14(21):6895-6906.es_ES
dc.identifier.issn1557-3265-
dc.identifier.urihttps://hdl.handle.net/10171/21771-
dc.description.abstractPURPOSE: Eradication of post-treatment residual myeloma cells is needed to prevent relapses, and immunostimulatory monoclonal antibodies (mAb) such as anti-CD137, CTLA-4, CD40, etc., which enhance the immune response against malignancies, represent a means of achieving this purpose. This study explores anti-CD137 mAbs for multiple myeloma treatment in preclinical models of the disease because they safely augment tumor immunity and are in clinical trials for other cancers. EXPERIMENTAL DESIGN: The antitumor effect of anti-CD137 mAb on mouse plasmacytomas derived from HOPC and NS0 cell lines was studied and compared with that of anti-CTLA-4, anti-CD40, and anti-ICAM-2 mAbs. The antitumor effect of anti-CD137 mAb was also examined in a mouse syngeneic disseminated myeloma (5TGM1) model, which more closely resembles human multiple myeloma. Depletions of specific cell populations and gene-targeted mice were used to unravel the requirements for tumor rejection. RESULTS: Agonistic mAb against CD137 and blocking anti-CTLA-4 mAb showed activity against i.p. HOPC tumors, resulting in extended survival of mice that also became immune to rechallenge. Anti-CD137 mAbs induced complete eradications of established s.c. NS0-derived tumors that were dependent on IFN-gamma, natural killer cells, and CD8(+) T lymphocytes. Natural killer cells accumulated in tumor draining lymph nodes and showed increased IFN-gamma production. Antitumor efficacy of anti-CD137 mAb was preserved in CD28-deficient mice despite the fact that CD28 signaling increases the expression of CD137 on CD8(+) T cells. Importantly, anti-CD137 mAb treatment significantly decreased systemic tumor burden in the disseminated 5TGM1 model. CONCLUSIONS: The immune-mediated antitumor activity of anti-CD137 mAb in mouse models holds promise for myeloma treatment in humans.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Association for Cancer Researches_ES
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/5K01CA104180-02;5P30CA054174-16-
dc.rightsinfo:eu-repo/semantics/closedAccess-
dc.subjectAdjuvants, Immunologic/therapeutic usees_ES
dc.subjectAntibodies, Monoclonal/therapeutic usees_ES
dc.subjectAntigens, CD137/immunologyes_ES
dc.subjectMultiple Myeloma/drug therapyes_ES
dc.subjectPlasmacytoma/drug therapyes_ES
dc.titleTherapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myelomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://clincancerres.aacrjournals.org/content/14/21/6895es_ES
dc.type.driverinfo:eu-repo/semantics/articlees_ES

Files in This Item:
There are no files associated with this item.


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.